Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series

Patients with psoriasis are at increased risk for psychiatric comorbidities, including suicidal ideation and behavior. For this reason, a careful assessment of patients, in particular for those reporting history of psychiatric symptoms is needed. We herein report a case series of 3 patients affected by major psychiatric disorders and moderate-to-severe psoriasis, successfully treated with secukinumab, an IL17A inhibitor, with a long-term psychiatric disease stability.